Skip to content
Menu

Voyager Therapeutics, Inc. VYGR

Full chart Compare
Set alert

Price alert · VYGR

All alert types
1.53 USD -0.08 (-4.97%)

Regular-session close

1.53 0.00 0.00%

After hours · Nov 20, 4:01 PM ET

1.51 Day range 1.65
1.52 52-week range 5.00
YTD
-61.07%
1 year
-62.59%

Discussion (14)

Member VYGR 1 week ago #1

$VYGR | Key takeaways from the Stifel Healthcare Conference:

🔹 VY7523: Tau-PET efficacy data expected “any day now.” Voyager is targeting ~50% slowing of tau accumulation, with potential partners interested if results are positive.

🔹 VY1706: First patient dosing expected in the coming months. Promising preclinical safety profile, including ~30x lower liver tropism vs. AAV9.

🔹 NeuroShuttle: Additional preclinical data coming in December.

My take: The VY7523 readout is the major near-term catalyst. Positive data could unlock significant value and partnership opportunities, but clinical risk remains high.

No new efficacy data were disclosed.

Full transcript:
https://www.investing.com/news/transcripts/voyager-therapeutics-at-stifel-2026-healthcare-conference-2026-tau-bets-93CH-5016649

Member VYGR 2 months ago #4

What a nice bear trap!

Member VYGR 3 months ago #8

$VYGR After looking at the weekly chart from several different angles (Volume Profile, VWAP, Donchian and Keltner Channels), I keep coming back to the same conclusion.
Around $3 looks like a major accumulation zone. Price has repeatedly tested this area without breaking down, while volatility has compressed to levels that often precede a significant move.
The next real volume wall doesn’t appear until roughly $4.20–4.50. If buyers can push through that range, the chart opens up considerably with much less historical resistance above.
To me, this no longer looks like a stock in a prolonged downtrend. It looks like a stock building a base before its next major move. The technical picture is tightening, while the fundamental catalysts are still ahead.
If the upcoming clinical and partnership news delivers, I believe the upside could be far greater than the downside from current levels. Time will tell, but this is one of the more asymmetric biotech setups I’ve seen in a while.

Member VYGR 3 years ago #9

$VYGR Just went back to the charts now I see why I forgot about it! It went well below the $6.01 and only recently shot back up!

Member VYGR 3 years ago #10

$VYGR Been here since $6.01 I forgot I even bought this! ? nice win so far!

Sign in to join the discussion